Access count of this item: 1027

Files in This Item:
File Description SizeFormat 
43_907.pdf404.07 kBAdobe PDFView/Open
Title: 表在性膀胱腫瘍に対する塩酸ピラルビシン(THP)の膀胱内注入による長期再発予防効果
Other Titles: A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer
Authors: 三木, 恒治  KAKEN_name
野々村, 祝夫  KAKEN_name
児島, 康行  KAKEN_name
奥山, 明彦  KAKEN_name
中野, 悦次  KAKEN_name
藤岡, 秀樹  KAKEN_name
若月, 晶  KAKEN_name
菅尾, 英木  KAKEN_name
竹山, 政美  KAKEN_name
清原, 久和  KAKEN_name
小出, 卓生  KAKEN_name
黒田, 秀也  KAKEN_name
瀬口, 利信  KAKEN_name
山口, 誓司  KAKEN_name
Author's alias: MIKI, Tsuneharu
KOJIMA, Yasuyuki
OKUYAMA, Akihiko
NAKANO, Etsuji
SUGAO, Hideki
KIYOHARA, Hisakazu
KOIDE, Takuo
KURODA, Hideya
SEGUTI, Toshinobu
Keywords: Bladdercancer
Issue Date: Dec-1997
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 43
Issue: 12
Start page: 907
End page: 912
Abstract: THP膀胱内注入療法は,対照群に比べdisease free intervalの延長は認めなかったが,初発症例群或いは多発症例群において有意の再発予防効果を認めた.副作用において臨床的に問題となるものは膀胱刺激症状であり,その他特に重篤な副作用はなかった
A prospective randomized study was conducted to evaluate the efficacy of prophylactic intravesical instillation of tetrahydropyranyladriamycin (THP) following complete transurethral resection (TUR) of superficial bladder cancer. A total of 80 patients were randomized into "THP" or "control" group. In the THP group, 20 mg of THP dissolved in 40 ml saline (or 5% dextrose) was administered intravesically once a week for 10 weeks, starting from about 7 days after TUR. In the control group, 40 ml saline was given with the same schedule. The patients were followed up by cystoscopy and urinary cytology every 3 months. The number of evaluable patients was 36 for the THP group and 37 for the control group. The non-recurrence rates in the THP group and control group were 79.4% versus 63.2% at 1 year and 69.8% versus 47.4% at 3 to 5 years, respectively. These figures were not statistically significant. However, THP instillation significantly reduced tumor recurrence rates for multiple tumors, and also tended to decrease recurrence rates for primary and pT1 tumors. Adverse effects were observed in 53.6% of the patients in the THP group, but they were tolerable. Our results suggest that intravesical THP instillation would not be effective for all patients with superficial bladder cancer. Further study is warranted in a selected group of patients.
PubMed ID: 9488944
Appears in Collections:Vol.43 No.12

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.